Streptococcal Toxic Shock Syndrome due to Streptococcus dysgalactiae subsp. equisimilis from Retroperitoneal Panniculitis during the treatment with anti-IL-6 receptor antibody: A Case Report.
Streptococcus dysgalactiae subsp. equisimilis
streptococcal toxic shock syndrome
tocilizumab
β-hemolytic streptococcus
Journal
Modern rheumatology case reports
ISSN: 2472-5625
Titre abrégé: Mod Rheumatol Case Rep
Pays: England
ID NLM: 101761026
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
25
10
2023
revised:
18
12
2023
accepted:
11
01
2024
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
13
1
2024
Statut:
aheadofprint
Résumé
A 53-year-old man with adult-onset Still's disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation.
Identifiants
pubmed: 38217091
pii: 7523753
doi: 10.1093/mrcr/rxae001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.